Calcium¹

alcium is the 5th most abundant element in the body with >99% residing in the skeleton as hydroxyapatite, a complex calcium phosphate molecule. This mineral supplies the strength to bones that support locomotion, but it also serves as a reservoir to maintain serum calcium levels. Calcium plays a central role in a wide range of essential functions. Its metabolism is regulated by 3 major transport systems: intestinal absorption, renal reabsorption, and bone turnover. Calcium transport in these tissues is regulated by a sophisticated homeostatic hormonal system that involves parathyroid hormone, 1,25 dihydroxyvitamin D, ionized calcium, and the calcium sensing receptor (1).

Deficiencies: The only source of calcium is from the diet. Calcium insufficiency manifests as decreased bone mass and osteoporotic fracture. In the rapidly growing child, calcium deficiency causes rickets. Low levels of intestinal calcium resulting from low dietary intakes have also been associated with increased risk of kidney stones and colon cancer (2). This is probably due to the decreased binding and increased absorption of oxalic acid, the main constituent of kidney stones, and of carcinogens such as bile acids.

Diet recommendations: The DRI for calcium were updated in 2010 (3). The biggest change since 1997 was the conversion from Adequate Intakes to Estimated Average Requirements and RDA for most groups. The RDA is 700 mg/d for children aged 1–3 y, 1000 mg/d for children aged 4–8 y, 1300 mg/d for adolescents, 1000 mg/d for younger adults, 1200 mg/d for women over age 51 y, and 1200 mg for men and women over the age of 70 y. Adolescents and older individuals are the most likely groups to be deficient in calcium in the US (3).

Food sources: Natural food sources of calcium are primarily dairy foods. A cup of milk or yogurt provides ⊠300 mg calcium. A plethora of calcium-fortified foods are available to consumers. The fortified food with the most similar nutrient profile to dairy is calciumfortified soymilk. Calcium-fortified orange juice also has many of the same nutrients as milk. Because milk provides a substantial portion of the calcium, phosphorus, riboflavin, and vitamin B-12 in the diet, it is difficult to meet nutrient needs without 3 servings/d of dairy foods as recommended by the Dietary Guidelines for Americans (4).

Clinical use of calcium: Calcium used clinically is usually prescribed as a dietary supplement. Various salts are in common use and include carbonate, phosphate, citrate, and citrate malate. These are usually taken in the form of pills, but a number of calcium-fortified juices are available, which, in general, are easier to take and are more digestible. Diseases treated with calcium supplements fall into 3 categories. The first are diseases in which the supplement is used to overcome calcium malabsorption by increasing the diffusion component of absorption. The supplement (expressed as grams of elemental calcium) is most effective when taken frequently and between meals. The diseases include hypoparathyroidism, malabsorptive bowel disease, and osteoporosis. Calcium supplements (≤2 g/d) are given in hypoparathyroidism to alleviate the hypocalcemia. However, because hypocalcemia is due to decreased renal calcium reabsorption, a dietary supplement has only marginal effects on increasing fasting serum calcium. A greater effect probably arises from chelation of dietary phosphate, which reduces the hyperphosphatemia and promotes an increase in fasting serum calcium (see below). In malabsorptive bowel disease, such as may occur with small bowel resection and celiac disease, calcium supplementation is used to optimize calcium absorption. The most common use of calcium supplementation (≤ 1.5 g/d) currently is for the prevention of age-related osteoporosis. It is given to increase calcium absorption and thus decrease bone resorption. At best, the calcium supplement prevents bone loss but has no effect on bone gain (5). The second category is in diseases in which the calcium supplement is used to chelate certain dietary anions, particularly phosphate. This use is largely restricted to chronic renal failure in which a reduction in phosphate absorption, and thus in serum phosphate, is the goal of treatment (6). In chronic renal failure, calcium supplements are effective phosphate binders. They are given in a dose of 0.5 g with each meal in contrast to supplements given to increase calcium absorption. In chronic renal failure (7), and to some extent in agerelated osteoporosis (8), concern is mounting that such high calcium supplements may exacerbate the propensity to develop vascular and soft tissue calcification. The 3rd category is in diseases with symptomatic gastric acidity. Calcium carbonate (Tums is the best known) is used as an antacid between meals to neutralize gastric acidity in gastroesophageal acid reflux disease and peptic ulcer disease.

Toxicity: The tolerable daily dietary upper intake level for calcium intake is set at 2500–3000 mg for adolescents and adults, 2500 mg for children, and 1000–1550 mg for infants (3). Intakes above these levels are considered to increase the risk of adverse effects, which are hypercalcemia and hypercalciuria, renal stone formation, vascular and soft tissue calcification, interactions with zinc and iron absorption, and constipation. These upper intake levels are about 2 to 3 times the RDA.

Sustained fasting hypercalcemia does not arise from calcium supplementation if the calcium/PTH/ 1,25 vitamin D axis is intact and renal function and acid-base balance are normal. However, abnormalities in these systems in combination with high-dietary calcium supplements or intakes may lead to hypercalcemia. It also occurs if high-calcium intake is given with high intakes of alkali that alter renal calcium reabsorption, as seen in Milk Alkali Syndrome (9). Hypercalciuria, high calcium excretion in the urine, arises from the renal excretion of the absorbed calcium that is in excess of the needs of the body stores, the major site being in bone. Hypercalciuria is a risk factor for renal stone formation due to the precipitation of calcium oxalate and calcium phosphate salts in urine. However, for calcium oxalate stones, an increase in urine oxalate is a much greater risk factor and for calcium phosphate stones, an increase in urine pH is a greater risk factor for stone formation (10).

Mineralization in bone, soft tissues, and blood vessels is a complex process (11). Although a supply of calcium and particularly phosphate are required, the relationship between the serum calcium and phosphate activity product and the presence of mineralization is never simple. Thus, the supply of calcium in the diet is only a weak determinant of soft tissue mineralization.

Binding of essential micronutrients such as iron and zinc is of concern in individuals at risk of these deficiencies. Constipation is said to be a complication of high-dietary calcium supplements, but it affects only some individuals and its pathophysiology is obscure.

Recent research: Studies of calcium interactions with other nutrients are an active area of research. For example, the interaction of dietary protein and calcium determines the risk of fracture (12). The role of vitamin D status, as assessed by serum 25 OH vitamin D concentrations, in calcium absorption continues to be a controversial field (3) and a number of intervention protocols are currently under study in children and adults.

There is recent concern over epidemiological evidence of increased risk of soft tissue calcification, but there are no proven underlying mechanisms identified to date (8). Several groups are exploring whether this is a causal relationship.

Connie M. Weaver*

Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907

Munro Peacock

Indiana University School of Medicine, Indianapolis, IN 46202

¹Author disclosures: C. M. Weaver is a member of the Pharmavite Advisory Board. M. Peacock, no conflicts of interest.

*To whom correspondence should be addressed. E-mail: weavercm@ purdue.edu.

Literature Cited

- Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010;5:s23–30.
- Weaver CM, Heaney RP. Calcium. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern nutrition in health disease. 10th ed. Baltimore (MD): Lippincott Williams & Wilkins; 2006. p 194–210.
- 3. IOM. Dietary Reference Intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.
- USDA. Report of the Dietary Guidelines Advisory Committee on the Dietary Guidelines for Americans, 2010. Washington, DC: USDA; 2010.
- Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, Hui SL, Johnston CC. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab. 2000;85: 3011–9.
- 6. Kazama JJ. Oral phosphate binders: history and prospects. Bone. 2009;45:s8–12.
- Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–52.
- Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, Gamble GD, Grey A, Reid IR. Vascular events in healthy older

women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336:262–6.

- Felsenfeld AJ, Levine BS. Milk alkali syndrome and the dynamics of calcium homeostasis. Clin J Am Soc Nephrol. 2006; 1:641–54.
- Robertson WG, Peacock M. The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron. 1980;26:105–10.
- Murshed M, McKee MD. Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr Opin Nephrol Hypertens. 2010;19:359–65.
- Sahni S, Apples A, McLean RR, Tucker K, Broe KE, Kiel DP, Handon MT. Protective effect of high protein and calcium intake on the risk of hip fracture in the Framingham offspring cohort. J Bone Miner Res. 2010;25:2494–500.